Co-trimoxazole prophylaxis in tropical countries in the era of highly active antiretroviral therapy: do we know enough?

Transactions of the Royal Society of Tropical Medicine and Hygiene

Volumn 101, Issue 11, 2007, Pages 1059-1060

  Lynen, Lut ^a   Jacobs, Jan ^a   Colebunders, Robert ^a  

^a INSTITUTE OF TROPICAL MEDICINE   (Belgium)

Author keywords

Chemoprophylaxis; Co trimoxazole; Drug tolerance; HAART; HIV; Toxicity

Indexed keywords

ANTIRETROVIRUS AGENT; COTRIMOXAZOLE; FANSIDAR; ISONIAZID; LAMIVUDINE PLUS NEVIRAPINE PLUS STAVUDINE; STAVUDINE; ZIDOVUDINE;

ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC RESISTANCE; CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERANCE; DRUG WITHDRAWAL; HEALTH CARE ACCESS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LONG TERM CARE; MALARIA FALCIPARUM; OPPORTUNISTIC INFECTION; PATIENT COMPLIANCE; PLASMODIUM FALCIPARUM; PNEUMOCYSTIS PNEUMONIA; PUBLIC HEALTH; REVIEW; RISK BENEFIT ANALYSIS; SURVIVAL; TOXOPLASMOSIS; TREATMENT DURATION; TROPICS; UNSPECIFIED SIDE EFFECT;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTI-INFECTIVE AGENTS; DEVELOPING COUNTRIES; DRUG THERAPY, COMBINATION; HUMANS; TREATMENT OUTCOME; TRIMETHOPRIM-SULFAMETHOXAZOLE COMBINATION;

EID: 34548822166     PISSN: 00359203     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.trstmh.2007.07.001     Document Type: Review

References (5)

1. Golub, J.E., Saraceni, V., Cavalcante, S., Pacheco, A.G., King, B., Moore, R.D., Chaisson, R.E., Moulton, L.H., Durovni, B., 2006. Tuberculosis (TB) incidence by HAART and isoniazid prophylactic therapy (IPT) in HIV-infected patients in Rio de Janeiro, Brazil, in: AIDS 2006-XVI International AIDS Conference; 13-18 August 2006; Toronto, Canada. Abstract No. MOPE0395.
2. Lowrance, D., Makombe, S., Harries, A., Yu, J., Aberle-Grasse, J., Eiger, O., Shiraishi, R., Marston, B., Ellerbrock, T., Libamba, E., 2007. Cotrimoxazole prophylaxis reduced the early mortality of HIV-infected patients on ART in Malawi, in: 14th Annual Conference on Retroviruses and Opportunistic Infections (CROI); 25-28 February 2007; Los Angeles, CA. Abstract No. 83.
3. Malamba S.S., Mermin J., Reingold A., Lule J.R., Downing R., Ransom R., Kigozi A., Hunt B.M., Hubbard A., Rosenthal P.J., and Dorsey G. Effect of cotrimoxazole prophylaxis taken by human immunodeficiency virus (HIV)-infected persons on the selection of sulfadoxine-pyrimethamine-resistant malaria parasites among HIV-uninfected household members. Am. J. Trop. Med. Hyg. 75 (2006) 375-380
4. Thera M.A., Sehdev P.S., Coulibaly D., Traore K., Garba M.N., Cissoko Y., Kone A., Guindo A., Dicko A., Beavogui A.H., Djimde A.A., Lyke K.E., Diallo D.A., Doumbo O.K., and Plowe C.V. Impact of trimethoprim-sulfamethoxazole prophylaxis on falciparum malaria infection and disease. J. Infect. Dis. 192 (2005) 1823-1829
5. WHO, 2006. Guidelines on co-trimoxazole prophylaxis for HIV-related infections among children, adolescents and adults. Recommendations for a public health approach. World Health Organization, Geneva. http://www.who.int/hiv/pub/guidelines/ctx/en/ [accessed 13 June 2007].